Insider Selling: Quidel Co. (QDEL) Director Sells 4,000 Shares of Stock

Quidel Co. (NASDAQ:QDEL) Director Jack W. Schuler sold 4,000 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $47.02, for a total transaction of $188,080.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Quidel Co. (NASDAQ QDEL) traded down $0.72 during trading hours on Friday, hitting $44.92. The stock had a trading volume of 126,184 shares, compared to its average volume of 334,417. The stock has a market cap of $1,556.38 and a PE ratio of -299.45. Quidel Co. has a 1-year low of $18.25 and a 1-year high of $49.47. The company has a quick ratio of 5.68, a current ratio of 6.28 and a debt-to-equity ratio of 0.70.

Quidel (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.21). The company had revenue of $50.89 million during the quarter, compared to analysts’ expectations of $50.47 million. Quidel had a negative return on equity of 2.36% and a negative net margin of 2.33%. The firm’s revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. research analysts expect that Quidel Co. will post -0.23 EPS for the current year.

A number of research analysts have recently commented on the stock. BidaskClub raised shares of Quidel from a “sell” rating to a “hold” rating in a research note on Saturday, December 2nd. Zacks Investment Research cut Quidel from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Piper Jaffray Companies reiterated a “buy” rating and set a $50.00 target price on shares of Quidel in a report on Friday, November 3rd. Canaccord Genuity reiterated a “buy” rating and set a $52.00 target price (up previously from $48.00) on shares of Quidel in a report on Thursday, December 21st. Finally, Barclays boosted their target price on Quidel from $45.00 to $49.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Quidel has an average rating of “Buy” and a consensus price target of $53.50.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Chicago Equity Partners LLC boosted its holdings in Quidel by 348.9% in the 4th quarter. Chicago Equity Partners LLC now owns 44,890 shares of the company’s stock worth $1,946,000 after acquiring an additional 34,890 shares during the period. Mesirow Financial Investment Management Equity Management purchased a new position in Quidel in the 4th quarter worth approximately $16,097,000. Schwab Charles Investment Management Inc. boosted its holdings in Quidel by 6.0% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 192,647 shares of the company’s stock worth $8,352,000 after acquiring an additional 10,843 shares during the period. Tandem Investment Advisors Inc. purchased a new position in Quidel in the 4th quarter worth approximately $640,000. Finally, Wolverine Trading LLC purchased a new position in Quidel in the 3rd quarter worth approximately $406,000. Hedge funds and other institutional investors own 92.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Quidel Co. (QDEL) Director Sells 4,000 Shares of Stock” was published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/02/02/jack-w-schuler-sells-4000-shares-of-quidel-co-qdel-stock/1824666.html.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.